In a small phase 2 randomized clinical trial this year, adults with alcohol use disorder saw a reduction in their alcohol consumption and cravings after receiving a weekly semaglutide shot
doi: 10.1080/0886022x.2024.2438857 206 TongJYangLLiuYYuYZhangLZhangZet al
Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
They are especially promising given their long duration of action, decreased risk of hypoglycemia, and added benefit of weight loss
I would have love to see a table with information about the individual participants, an idea of WHEN during the 16 weeks the periods occurred, if they continued again afterward Study #3 This third study was similar in recruiting 27 women with HA, and dividing them into low- and normal-LH groups
Both contain the prescribed active pharmaceutical ingredient and work through identical mechanisms